Pharma Mar SA
OTC:PHMMF
Pharma Mar SA
OTC:PHMMF
Price:
31.15 USD
16.01%
Updated:
May 6, 2024
Section:
Relative Value
The Relative Value of one
PHMMF
stock under the Base Case scenario is
55.48
USD.
Compared to the current market price of 31.15 USD,
Pharma Mar SA
is
Undervalued by 44%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
PHMMF
Relative Value
Base Case
55.48
USD
Undervaluation 44%
Valuation Multiples
Multiples Across Competitors
PHMMF Competitors Multiples
Pharma Mar SA Competitors
Pharma Mar SA Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| ES |
|
Pharma Mar SA
OTC:PHMMF
|
557.4m USD | 3.5 | 490.3 | 255.6 | -103.4 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
285.6B USD | 5.3 | 59.3 | 12.9 | 19.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
159.7B USD | 5.7 | 23.8 | 17.3 | 26 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
104.4B USD | 8 | 26.4 | 17.8 | 19.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.6B USD | 10.5 | 28.6 | 22.9 | 24 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133.1B AUD | 6.2 | 35.6 | 21.6 | 26.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
80.3B USD | 2.9 | 165.8 | 6.6 | 8.7 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
45.9B USD | 6.7 | -9.7 | -10.5 | -8.9 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
32.1B USD | 3.3 | 27.5 | 14.1 | 17.6 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.2T KRW | 18 | 73.1 | 44.7 | 61.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
